NSEChange in Auditors3d ago · 24 Jul 2026, 07:27 pm

Change in Auditors

Neogen Chemicals Limited · NEOGEN

✦ AI SummaryAuditor Change

Neogen Chemicals Limited has informed the Exchange regarding Change in Auditors of the company. The Board of Directors had at its meeting held today considered and approved various items including the Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended June 30, 2026, and the convening of the 37th Annual General Meeting (AGM) of the Company on Friday, August 21, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Neogen Chemicals Limited has informed the Exchange regarding Change in Auditors of the company.

Attachments (1)

📄

NEOGEN_24072026192557_BMoutcome.pdf

pdf

Download →
View document text
July 24, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services Listing Department, Floor 25, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Scrip Code No: 542665 Mumbai – 400 051 Debt Segment Code: 977028 Company Symbol: NEOGEN Sub: Outcome of Board Meeting held on Friday July 24, 2026. Ref.: Regulation 30 33, 51 and 52 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). Dear Sir/Madam, With reference to the captioned subject and pursuant to Regulation 30, 33, 51 and 52 read with Schedule III, we wish to inform you that the Board of Directors of Neogen Chemicals Limited (“the Company”) had at its meeting held today i.e., Friday July 24, 2026, at 2:00 p.m. and concluded at 6:30 p.m., inter alia considered and approved the following: 1. The Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended June 30, 2026, pursuant to Regulation 33 of the Listing Regulations along with the “Limited Review Report” thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith as Annexure I; A copy of the said Financial Results containing disclosures required under Regulations 33, 52, 54 and other provisions of the Listing Regulations, as applicable, together with the Limited Review Reports by M/s. Chandabhoy Jassoobhoy, Chartered Accountants and security cover certificate under Regulation 54(3) and 56(1)(d) of the Listing Regulations is enclosed herewith as Annexure II. 2. Pursuant to Regulation 32 of Listing Regulations, as amended from time to time, we enclose herewith as Annexure III Statement of Deviation/ Variation in utilization of funds (“Statement”) for the quarter ended June 30,2026, which has been duly reviewed by the Audit Committee. 3. The Integrated Annual Report for FY 2025-26 including Directors’ Report with annexures, Management Discussion and Analysis Report, Business Responsibility and Sustainability Report alongwith Reasonable Assurance report and Corporate Governance Report and Notice convening 37th Annual General Meeting (“AGM”) and others of the Company; 4. The convening of the 37th AGM of the Company on Friday, August 21, 2026, at 5.00 p.m. IST through video conferencing (VC) and Other Audio-Visual Means (OAVM) in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India; 5. Record date/Cutoff Date pursuant to Regulation 42 of Listing Regulations, as Thursday, August 13, 2026, for deciding eligibility of members for remote e-voting and final dividend for the financial year 2025-26 and the Register of Members and Share Transfer Register will remain closed from Friday, August 14, 2026 to Friday, August 21, 2026 (both days inclusive) for the purpose of ascertaining the eligible members who shall be entitled to receive the dividend, if approved by the members at the 37th AGM of the Company; Registered Office: 1002, Dev Corpora, Cadbury Junction, E: sales@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 6. Granting of in-principle approval for raising of funds upto Rs. 600 crores in Indian/ foreign currency by way of issue of any instrument or security(ies) including equity shares, or any other eligible securities or any combination thereof, in one or more tranche, including by way of a qualified institutional placements (QIP), in accordance with the applicable provision of the Companies Act, 2013 read with the Companies (Prospectus and Allotment of Securities) Rules, 2014, SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018, SEBI Listing Regulations and other applicable laws (each as amended from time to time), or through any other permissible mode or any combination thereof, of any of the above, to the eligible investors, in such manner, and on such terms and conditions as may be deemed appropriate by the Board of Directors in its absolute discretion, subject to the receipt of necessary approvals, including the approval of the members of the Company at a general meeting or through postal ballot and such other regulatory I statutory approvals as may be required. The details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time (“SEBI Circulars”), with respect to in-principle approval granted by the Board for raising of funds is enclosed herewith as Annexure IV. 7. Appointment of CNK & Associates as the Internal Auditor of the Company for F.Y. 2026-27. The details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time (“SEBI Circulars”), with respect to appointment of Internal Auditor is enclosed herewith as Annexure V. 8. Further the Board of Neogen Morita New Materials Limited (NML) in its meeting held today approved the following: a) Increase in Borrowing powers of the Company under section 180 (1) (c) of the Companies Act, 2013 upto Rs. 500 Crore and subsequent creation of security/ charge on the properties of NML, both present and future, in favour of lenders, subject to approval of the shareholders of NML. The above information is also being uploaded on the Company’s website at https://neogenchem.com/financial-performance/ , https://neogenchem.com/announcements/ and at the website of the NSE (www.nseindia.com) and BSE (www.bseindia.com). Kindly take the above information on your records. Yours faithfully, For Neogen Chemicals Limited Unnati Kanani Company Secretary & Compliance Officer Mem. No: A35131 Place: Thane Encl.: As above Registered Office: 1002, Dev Corpora, Cadbury Junction, E: sales@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 215-216, A To Industrial Estate, . Gate no. 3, 2nd floor, I GK Marg, Lower Pa rel, I Mumbai-400 013. J India Phone: +9122 4619 7023/24/25 : +91 22 4606 7023 Email : mail@cnj.in Web : www.cnj.in Independent Auditors' Limited Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Board of Directors of \leogen Chemicals Limited l. We have reviewed the accompanying statement of unaudited standalone financial results of Neogen Chemicals Limited (''the Company") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standards on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of [Showing first 8,000 characters — download PDF for full document]